Atavistik Bio announced a strategic research collaboration with Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) to discover and develop novel small molecule therapies targeting multiple targets in cardiovascular, renal, and metabolic (CVRM) diseases, in a deal worth a USD 70 million upfront payment and up to USD 1.9 billion in potential milestone payments.
Contents
Transaction Snapshot
| Item | Detail |
|---|---|
| Deal Type | Strategic research collaboration |
| Parties | Atavistik Bio and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) |
| Therapeutic Focus | CVRM – cardiovascular, renal, and metabolic diseases, multiple targets |
| Upfront Payment | USD 70 million |
| Milestones | Up to USD 1.9 billion in additional research, development, and commercial milestone payments |
| Royalties | Tiered royalties on future net sales of any approved medicines |
| Atavistik Role | Discovery and research activities for the collaboration targets |
| Roche Role | Further preclinical and clinical development, regulatory, and commercialization |
| Announcement Date | 24 Sep 2026 |
Collaboration Structure & Platform Technology
- AMPS Platform: The collaboration will leverage Atavistik Bio’s proprietary AMPS drug discovery platform and its expertise in allosteric drug discovery to identify novel functional binding pockets and advance selective small molecule therapies targeting CVRM disease targets.
- Cryptic Pocket Discovery: By discovering cryptic, biologically relevant binding pockets – transient or hidden sites not apparent in static protein structures – the platform enables new approaches to develop differentiated small molecules against targets invisible to conventional screening methods.
- Hard‑to‑Drug Targets: The cryptic‑pocket approach is aimed at historically hard‑to‑drug, therapeutically important targets, where traditional small‑molecule discovery has stalled despite high clinical value.
- Allosteric Modality Advantage: Allosteric molecules act at sites distinct from the active (orthosteric) site, often enabling greater selectivity, tunable modulation, and access to mechanisms unreachable by conventional inhibitors.
Disease Area Background – CVRM
- Burden: Cardiovascular, renal, and metabolic diseases – including heart failure, chronic kidney disease, obesity, and type 2 diabetes and their interlinked complications – represent one of the largest global causes of morbidity and mortality, with tightly connected pathophysiology across organ systems.
- Industry Focus: CVRM has become a central battleground for big pharma R&D, evidenced by the rapid expansion of incretin‑based therapies and intense pipeline competition across cardiometabolic indications.
- Discovery Bottleneck: Despite the clinical demand, many CVRM‑relevant proteins remain undruggable with conventional chemistry – creating an opening for platform‑based discovery partners offering novel modalities such as cryptic‑pocket allosteric small molecules.
Market Impact & Outlook
- Big Pharma Validation: A USD 70 million upfront – a substantial sum for a research‑stage collaboration – plus up to USD 1.9 billion in milestones signals strong conviction from Roche in Atavistik Bio’s AMPS platform and cryptic‑pocket discovery capability.
- Strategic Fit for Roche: The deal extends Roche’s CVRM pipeline with multi‑target optionality in one of the industry’s highest‑priority therapeutic areas, without bearing early discovery risk.
- Platform Economics: The combination of upfront cash, milestone payments, and tiered royalties provides Atavistik Bio with non‑dilutive funding and long‑term participation in any commercial success of collaboration‑derived medicines.
- Biotech Funding Signal: The transaction adds to the momentum for AI‑ and platform‑driven drug discovery companies securing large‑pharma partnerships, reinforcing the valuation logic of next‑generation discovery engines.
- Execution Watch Items: Identification and progression of collaboration targets through discovery, handoff to Roche’s preclinical/clinical development, and future expansion of the AMPS platform into additional partnerships (specific targets and timelines not disclosed).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the research collaboration between Atavistik Bio and Roche, including target discovery, milestone achievement, regulatory outcomes, and commercial expectations. Actual results may differ materially due to risks including discovery and preclinical setbacks, clinical failure, competitive dynamics, and the early‑stage nature of the collaboration programs..-Fineline Info & Tech
